
personnel |
current programs |
patient intervention materials |

Our lab focuses on the 13-amino-acid neuropeptide neurotensin, which was first discovered in the brain more than 30 years ago. Evidence suggests that brains affected by Alzheimer's disease have neurotensin deficits in areas involved with memory function. Neurotensin also may be involved in Parkinson's disease and schizophrenia. Our goal is to develop new drugs that stimulate brain receptors for neurotensin in an effort to reverse or stop the progression of these neuropsychiatric diseases.
| |

|
LEGAL RESTRICTIONS AND TERMS OF USE APPLICABLE TO THIS SITE
Use of this site signifies your agreement to the terms of use.
© 2012 Mayo Foundation for Medical Education and Research. All rights reserved.